Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity.
The top deals announced or closed in 2013 created supergiants in the diagnostics and renal device spaces for the first time. One transaction helped a major device player expand its orthopedic device offerings. Another $1.1 billion purchase helped a pharmaceutical giant become a major maker of a birth control device implant in one fell swoop. Another international med tech player, always on the lookout for new business lines, snatched up a buzz-worthy maker of an endoscopic pill camera in a deal announced at the end of 2013 that just closed in February, gaining new revenue possibilities through a smart acquisition.
Some UCLA scientists are hard at work looking at how to tap into the potential of Google Glass for medical use. Nanowerk reported that researchers have developed an app for the futuristic device that could enable instant, wireless diagnostic testing for HIV, types of cancer and other diseases. Credit a team from the university system's California NanoSystems Institute and the David Geffen School of Medicine for the advance. The journal ACS Nano details their findings.
Neuromodulation is one of those medical device industry segments that's been around for a while. Generally, it involves implants through which electrical stimulation of the spinal cord, the brain or a peripheral nerve helps alleviate pain.
Neuromodulation is also one of those medical device industry segments that are poised for some major growth in the coming years, based on projections compiled by the research outfit EvaluateMedTech. Part of that comes as Medtronic and other companies explore a much wider use for the treatment, seeking to determine, for example, whether it can enable long-term relief (through deep brain stimulation) of Parkinson's-related symptoms. Neuromodulation also shows promise and gives hope as a potential treatment for depression and other psychiatric disorders. And the list goes on.
POPULAR COMMENT THREADS
In 2010, Olympus bought Stryker's troubled OP-1 putty for $60 million, hoping to expand its market. Now, the Japanese maker of medical devices and cameras says it's selling the Lebanon, NH, plant where the putty is made at a bargain price--and if it can't make a deal it will close the facility.
German medical device manufacturer Gerresheimer AG is expanding its presence in Georgia to take advantage of a boom in inhaler and insulin-pen demand. The investment is in the millions of dollars and will create additional 120 jobs in the process.
Smith & Nephew has inked a co-marketing deal with OrthoSensor involving one of the company's orthopedic surgical tools. Neither side is discussing financial details.
For the first time, a blood test appears to predict with an impressive level of certainty whether patients will develop Alzheimer's disease within three years.
Mainstay Medical's implantable neuromodulation device scores Australian approval for clinical trials
Mainstay Medical won approval from Ethics Committees in Australia to begin a clinical trial of its implantable neuromodulation device.
Invuity's $36 million Series E debt and equity round announced last week will back a beefed up sales force, plus an expanded headquarters and manufacturing operation for its illumination technology and surgical tools. But is an IPO next? CEO Phil Sawyer isn't saying either way, choosing to remain mum about the San Francisco-based company's future financing plans.
From Our Sister Sites
The National Institute of Allergy and Infectious Diseases has awarded a 7-year, $9.8 million grant to develop an AIDS vaccine to four Seattle-based research organizations and Rockefeller University.
A British drugmaker has landed in the middle of the controversy over Sweetwater, Texas' Rattlesnake RoundUp